Neuroleptic malignant syndrome

British Journal of Anaesthesia

Volumn 85, Issue 1, 2000, Pages 129-135

  Adnet, P ^a   Lestavel, P ^a   Krivosic Horber, R ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Anaesthetics i.v.; Hyperthermia; Malignant; Neuroleptics; Pharmacology

Indexed keywords

BENZODIAZEPINE; BROMOCRIPTINE MESILATE; DANTROLENE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT;

CATATONIA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ELECTROCONVULSIVE THERAPY; HEAT STROKE; HUMAN; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKELETAL MUSCLE;

DIAGNOSIS, DIFFERENTIAL; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; RISK FACTORS;

EID: 0033624222     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/85.1.129     Document Type: Article

References (50)

1. Adityanjee PA, Singh S, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatr 1988; 153: 107-11
2. Adnet PJ, Krivosic-Horber RM, Adamantidis MM et al. The association between the neuroleptic malignant syndrome and malignant hyperthermia. Acta Anaesthesiol Scand 1989; 33: 676-80
3. Adnet PJ, Krivosic-Horber RM, Adamantidis MM, Haudecoeur G, Reyford HG, Dupuis BA. Is resting membrane potential a possible indicator of viability of muscle bundles used in the in vitro caffeine contracture test? Anesth Analg 1991; 74: 105-11
4. Adnet PJ, Krivosic-Horber RM, Adamantidis MM, Reyford H, Cordonnier C, Haudecoeur G. Effects of calcium-free solution, calcium antagonists, and the calcium agonist BAY K 8644 on mechanical responses of skeletal muscle from patients susceptible to malignant hyperthermia. Anesthesiology 1991; 75: 413-19
5. Araki M, Takagi A, Higuchi I, Sugita H. Neuroleptic malignant syndrome: caffeine contracture of single muscle fibers and muscle pathology. Neurology 1988; 38: 297-301
6. Berardi D, Amore M, Keck PE, Troia M, Dellatti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatr 1998; 44: 748-54
7. Blingh J, Cottle WH, Maskrey M. Influence of ambient temperature on the thermoregulatory responses to 5 hydroxy-tryptamine, noradrenalin and acetylcholine injected into the lateral cerebral ventricles of sheep, goats and rabbits. J Physiol 1971; 212: 377-92
8. Bollaert PE, Robin-Lherbier B, Escange JM et al. Phosphorus nuclear magnetic resonance: evidence of abnormal skeletal muscle metabolism in chronic alcoholics. Neurology 1989; 39: 821-4
9. Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharmacol 1984; 3: 302-7
10. Burke RE, Fahn S, Mayeux R. Neuroleptic malignant syndrome caused by dopamine depleting drugs in a patient with Huntington's chorea. Neurology (NY) 1981; 31: 1022-6
11. Cao L, Katz RH. Acute hypernatremia and neuroleptic malignant syndrome in Parkinson disease. Am J Med Sci 1999; 318: 67-8
12. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatr 1980; 41: 79-83
13. Caroff SN, Rosenberg H, Fletcher JE, Heiman-Patterson TD, Mann SC. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987; 67: 20-5
14. Cox B, Kerwin R, Lee TE. Dopamine receptors in the central thermoregulatory pathways of the rat. J Physiol (Lond.) 1978; 282: 471-83
15. Delacour JL, Daoudal P, Chapoutot JL, Rocq B. Traitement du syndrome malin des neuroleptiques par le dantroléne. Nouv Presse Méd 1981; 10: 3572-3
16. Delay J, Pichot P, Lempiere T, Blissalde B, Peigne F. Un neuroleptique majeur non phenothiazinique et non réserpinique, l'halopéridol, dans le traitement des psychoses. Ann Med Psychol 1960; 18: 145-52
17. Denborough MA, Collins SP, Hopkinson KC. Rhabdomyolysis and malignant hyperpyrexia. Br Med J 1985; ii: 1878
18. Fleischbacker WW, Unterweger B, Kane JM, Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 1990; 81: 3-5
19. Gallant EM, Fletcher TF, Goettl VM, Rempel WE. Porcine malignant hyperthermia: cell injury enhances halothane sensitivity of biopsies. Muscle Nerve 1986; 9: 174-84
20. Gelenberg AJ, Bellinghausen B, Wojcik JD, Falk WE, Sachs GS. Aprospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatr 1988; 145: 517-8
21. Gurrera RJ. Sympathoadrenal hyperactivity and the ethiology of neuroleptic malignant syndrome. Am J Psychiatr 1999; 156: 169-80
22. Guze BH, Baxter CR. Current concepts. Neuroleptic malignant syndrome. New Engl J Med 1985; 313: 163-6
23. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatr 1998; 155: 1113-6
24. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology 1981; 31: 132-7
25. Hermesh H, Aizenberg D, Weizman A. A successful electroconvulsive treatment of neuroleptic malignant syndrome. Acta Psychiatr Scand 1987; 75: 237-9
26. Hermesh H, Aizenberg D, Lapidot M, Munitz H. Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am J Psychiatr 1988; 145: 1431-4
27. Kawanishi C, Hanihara T, Maruyama Y et al. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. Psychiatr Gen 1997; 7: 127-9
28. Kawanishi C, Hanihara T, Shimoda Y et al. Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HTIA and 5HT2A receptor genes. Am J Psychiatr 1998; 155: 1275-7
29. Keck PE, Pope H, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatr 1989; 46: 914-8
30. Keck PE, Harrisson G, Pope JR, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991; 148: 880-2
31. Kelkar W, Jindal MN. Chlorpromazine-induced contracture of frog rectus abdominis muscle. Pharmacology 1974; 12: 32-8
32. Krivosic-Horber R, Adnet P, Guevart E, Theunynck D, Lestavel P. Neuroleptic malignant syndrome and malignant hyperthermia. Br J Anaesth 1987; 59: 1554-6
33. Lazarus A. Differentiating neuroleptic-related heatstroke from neuroleptic malignant syndrome. Psychosomatics 1989; 30: 454-6
34. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatr 1985; 142: 1137-45
35. Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatr 1992; 16: 425-43
36. McCarron MM, Boettger ML, Peck JI. A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatr 1982; 43: 381-2
37. McCarthy A. Fatal recurrence of neuroleptic malignant syndrome. Br J Psychiatr 1988; 152: 558-9
38. Miyatake R, Iwahashi K, Matsushita M, Nakamura K, Suwaki H. No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated with malignant hyperthermia. J Neurol Sci 1996; 143: 161-5
39. Pope AG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatr 1986; 143: 1227-33
40. Reyford HG, Cordonner C, Adnet PJ, Krivosic-Horber RM, Bonte CA. The in vitro exposure of muscle strips from patients with neuroleptic malignant syndrome cannot be correlated with the clinical features. J Neurol Sci 1990; 98 (Suppl 6.6): 527
41. Rosenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Int Med 1989; 149: 1927-31
42. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatr 1997; 154: 1156-8
43. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337-47
44. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatr 1989; 50: 18-25
45. Takagi A. Chlorpromazine and skeletal muscle: a study of skinned single fibers of the guinea pig. Exp Neurol 1981; 734: 477-86
46. Tanii H, Taniguchi N, Niigawa H et al. Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia and high serum creatine phosphokinase level. Brain Res 1996; 743: 263-70
47. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia susceptibility. Br J Anaesth 1984; 56: 1267-9
48. Thomas P, Maron M, Rascle C et al. Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol Psychiatr 1998; 43: 303-5
49. Tollefson G. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. J Clin Psychopharmacol 1982; 2: 266-70
50. Toru M, Matsuda O, Makaguchi K. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drug. J Nervous Mental Dis 1981; 169: 324-7